BACKGROUND: Collagen IX is an integral cartilage extracellular matrix component important in skeletal development and joint function. RESULTS: Proteomic analysis and validation studies revealed novel alterations in collagen IX null cartilage. CONCLUSION: Matrilin-4, collagen XII, thrombospondin-4, fibronectin, βig-h3, and epiphycan are components of the in vivo collagen IX interactome. SIGNIFICANCE: We applied a proteomics approach to advance our understanding of collagen IX ablation in cartilage. The cartilage extracellular matrix is essential for endochondral bone development and joint function. In addition to the major aggrecan/collagen II framework, the interacting complex of collagen IX, matrilin-3, and cartilage oligomeric matrix protein (COMP) is essential for cartilage matrix stability, as mutations in Col9a1, Col9a2, Col9a3, Comp, and Matn3 genes cause multiple epiphyseal dysplasia, in which patients develop early onset osteoarthritis. In mice, collagen IX ablation results in severely disturbed growth plate organization, hypocellular regions, and abnormal chondrocyte shape. This abnormal differentiation is likely to involve altered cell-matrix interactions but the mechanism is not known. To investigate the molecular basis of the collagen IX null phenotype we analyzed global differences in protein abundance between wild-type and knock-out femoral head cartilage by capillary HPLC tandem mass spectrometry. We identified 297 proteins in 3-day cartilage and 397 proteins in 21-day cartilage. Components that were differentially abundant between wild-type and collagen IX-deficient cartilage included 15 extracellular matrix proteins. Collagen IX ablation was associated with dramatically reduced COMP and matrilin-3, consistent with known interactions. Matrilin-1, matrilin-4, epiphycan, and thrombospondin-4 levels were reduced in collagen IX null cartilage, providing the first in vivo evidence for these proteins belonging to the collagen IX interactome. Thrombospondin-4 expression was reduced at the mRNA level, whereas matrilin-4 was verified as a novel collagen IX-binding protein. Furthermore, changes in TGFβ-induced protein βig-h3 and fibronectin abundance were found in the collagen IX knock-out but not associated with COMP ablation, indicating specific involvement in the abnormal collagen IX null cartilage. In addition, the more widespread expression of collagen XII in the collagen IX-deficient cartilage suggests an attempted compensatory response to the absence of collagen IX. Our differential proteomic analysis of cartilage is a novel approach to identify candidate matrix protein interactions in vivo, underpinning further analysis of mutant cartilage lacking other matrix components or harboring disease-causing mutations.
BACKGROUND: Collagen IX is an integral cartilage extracellular matrix component important in skeletal development and joint function. RESULTS: Proteomic analysis and validation studies revealed novel alterations in collagen IX null cartilage. CONCLUSION:Matrilin-4, collagen XII, thrombospondin-4, fibronectin, βig-h3, and epiphycan are components of the in vivo collagen IX interactome. SIGNIFICANCE: We applied a proteomics approach to advance our understanding of collagen IX ablation in cartilage. The cartilage extracellular matrix is essential for endochondral bone development and joint function. In addition to the major aggrecan/collagen II framework, the interacting complex of collagen IX, matrilin-3, and cartilage oligomeric matrix protein (COMP) is essential for cartilage matrix stability, as mutations in Col9a1, Col9a2, Col9a3, Comp, and Matn3 genes cause multiple epiphyseal dysplasia, in which patients develop early onset osteoarthritis. In mice, collagen IX ablation results in severely disturbed growth plate organization, hypocellular regions, and abnormal chondrocyte shape. This abnormal differentiation is likely to involve altered cell-matrix interactions but the mechanism is not known. To investigate the molecular basis of the collagen IX null phenotype we analyzed global differences in protein abundance between wild-type and knock-out femoral head cartilage by capillary HPLC tandem mass spectrometry. We identified 297 proteins in 3-day cartilage and 397 proteins in 21-day cartilage. Components that were differentially abundant between wild-type and collagen IX-deficient cartilage included 15 extracellular matrix proteins. Collagen IX ablation was associated with dramatically reduced COMP and matrilin-3, consistent with known interactions. Matrilin-1, matrilin-4, epiphycan, and thrombospondin-4 levels were reduced in collagen IX null cartilage, providing the first in vivo evidence for these proteins belonging to the collagen IX interactome. Thrombospondin-4 expression was reduced at the mRNA level, whereas matrilin-4 was verified as a novel collagen IX-binding protein. Furthermore, changes in TGFβ-induced protein βig-h3 and fibronectin abundance were found in the collagen IX knock-out but not associated with COMP ablation, indicating specific involvement in the abnormal collagen IX null cartilage. In addition, the more widespread expression of collagen XII in the collagen IX-deficient cartilage suggests an attempted compensatory response to the absence of collagen IX. Our differential proteomic analysis of cartilage is a novel approach to identify candidate matrix protein interactions in vivo, underpinning further analysis of mutant cartilage lacking other matrix components or harboring disease-causing mutations.
Authors: Markus Schmitz; Alexander Becker; Alexander Schmitz; Christian Weirich; Mats Paulsson; Frank Zaucke; Robert Dinser Journal: J Biol Chem Date: 2006-08-23 Impact factor: 5.157
Authors: Matthew P Leighton; Seema Nundlall; Tobias Starborg; Roger S Meadows; Farhana Suleman; Lynette Knowles; Raimund Wagener; David J Thornton; Karl E Kadler; Raymond P Boot-Handford; Michael D Briggs Journal: Hum Mol Genet Date: 2007-05-21 Impact factor: 6.150
Authors: Karen L Posey; Kurt Hankenson; Alka C Veerisetty; Paul Bornstein; Jack Lawler; Jacqueline T Hecht Journal: Am J Pathol Date: 2008-05-08 Impact factor: 4.307
Authors: Katarzyna A Piróg-Garcia; Roger S Meadows; Lynette Knowles; Dick Heinegård; David J Thornton; Karl E Kadler; Raymond P Boot-Handford; Michael D Briggs Journal: Hum Mol Genet Date: 2007-06-22 Impact factor: 6.150
Authors: Ebbe Toftgaard Poulsen; Kasper Runager; Nadia Sukusu Nielsen; Marie V Lukassen; Karen Thomsen; Paige Snider; Olga Simmons; Henrik Vorum; Simon J Conway; Jan J Enghild Journal: FEBS J Date: 2017-11-23 Impact factor: 5.542
Authors: Christopher R Paradise; Catalina Galeano-Garces; Daniela Galeano-Garces; Amel Dudakovic; Todd A Milbrandt; Daniel B F Saris; Aaron J Krych; Marcel Karperien; Gabriel B Ferguson; Denis Evseenko; Scott M Riester; Andre J van Wijnen; A Noelle Larson Journal: Gene Date: 2018-05-25 Impact factor: 3.688
Authors: Kei Imagawa; María C de Andrés; Ko Hashimoto; Eiji Itoi; Miguel Otero; Helmtrud I Roach; Mary B Goldring; Richard O C Oreffo Journal: Arthritis Rheumatol Date: 2014-11 Impact factor: 10.995